|
May 13
|
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 13
|
Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript
|
|
May 12
|
With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest
|
|
May 10
|
Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis
|
|
May 9
|
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 7
|
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
|
|
May 2
|
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
|
|
Apr 30
|
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
|
|
Apr 15
|
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
|
|
Apr 12
|
Invivyd Announces CEO Transition
|
|
Apr 7
|
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
|
|
Apr 4
|
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
|
|
Mar 28
|
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
|
|
Mar 22
|
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
|
|
Mar 22
|
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
|
|
Jan 19
|
When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?
|
|
Jan 12
|
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
|
|
Dec 23
|
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?
|
|
Dec 19
|
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
|
|
Dec 18
|
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
|